2cureX

2cureX P/TBV

Delisted·Sep 2, 2026

The Price to Tangible Book Value (P/TBV) of 2cureX (2CUREX.ST) as of Oct 29, 2026 is 8.27. In the previous year, Price to Tangible Book Value (P/TBV) was 3.49 — a change of 136.87% (higher).

P/TBV

8.27

YoY

136.87%

Last updated:

Price to Tangible Book Value (P/TBV) of 2cureX is 2024 8.27 . Price to Tangible Book Value (P/TBV) of 2cureX was 2023 3.49 . It decreases by 136.87% higher compared to the previous year.

The 2cureX P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2017
2.08 SEK
Jan 1, 2018
3.10 SEK
Jan 1, 2019
1.50 SEK
Jan 1, 2020
0.72 SEK
Jan 1, 2021
0.57 SEK
Jan 1, 2022
0.98 SEK
Jan 1, 2023
3.49 SEK
Jan 1, 2024
8.27 SEK
The 2cureX P/TBV history
YEARP/TBVYoY
8.27+136.87%
3.49+256.30%
0.98+72.76%
0.57-20.82%
0.72-52.30%
1.50-51.49%
3.10+48.57%
2.08-60.89%
5.33+3.46%
5.15+9.27%
4.71—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

2cureX Stock analysis

What does 2cureX do? 2cureX AB develops anti-cancer treatments through research and development, focusing on diagnostic substances to optimize cancer patient care. Its key product, IndiTreat - CRC, enables healthcare professionals to test chemotherapies and experimental treatments using three-dimensional micro tumors created from patient tumor samples. The company also offers IndiTreat - OVA for ovarian cancer and IndiTreat - KDN for kidney cancer, forming its product pipeline. 2cureX AB operates through 2cureX A/S, targeting healthcare providers and oncology specialists who seek personalized treatment solutions for cancer patients. The company generates revenue by providing diagnostic services and product candidates to healthcare institutions. IndiTreat - CRC, IndiTreat - OVA, and IndiTreat - KDN are sold as diagnostic tools to hospitals and clinics specializing in cancer treatment. These products help medical teams select the most effective therapies for individual patients, reducing trial-and-error in cancer care. 2cureX AB's business model relies on the adoption of its diagnostic platform by oncology departments seeking precision medicine approaches. 2cureX AB's primary customers are healthcare professionals and institutions involved in cancer treatment, particularly those focused on colorectal, ovarian, and kidney cancers. The firm's diagnostic solutions are used to guide treatment decisions, with IndiTreat - CRC being the most advanced product in its pipeline. By offering tailored diagnostic services, 2cureX AB supports healthcare providers in delivering targeted therapies, aligning with the growing demand for personalized cancer care strategies. 2cureX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 2cureX stock

Price to Tangible Book Value (P/TBV) of 2cureX is 8.27 in 2024.

Price to Tangible Book Value (P/TBV) of 2cureX changed from 3.49 to 8.27, representing a 136.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) 2cureX since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s 2cureX with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — 2cureX

All Key Metrics — 2cureX